“…The conventional methods of cancer treatments, including surgery, radiotherapy, and chemotherapy, have several limitations, such as poor prognosis, severe side effects, and drug resistance. − Though emerging clinical ablation procedures have been gradually applied to cancer treatment, such as microwave ablation and radiofrequency ablation, the stubborn coagulative necrosis tissue, invasive increased risk of bleeding, and easy relapse make it necessary to find other more effective or novel cancer treatment strategies. − Ultrasound (US)-augmented tumor ablation with sono-catalysts has emerged as a promising therapeutic modality due to high tissue penetration, nonionizing performance, and low cost of US-based therapies. , Typically, the sono-catalysts activated by the US can induce tumor cell apoptosis or necrosis through generating reactive oxygen species (ROS), which can lead to DNA, lipids, and proteins damages and cause structural failures of tumor cells. − Though these sono-catalysts including organic porphyrins and inorganic TiO 2 nanoparticles have been widely developed for tumor therapies, their low ROS generation and treatment efficacies are still unsatisfactory. − Therefore, it is particularly important to develop novel biocatalysts with high-efficiency ROS generation for US-augmented ablation of tumors.…”